RAJANT HOSTS UNICEF FUNDRAISER TO SUPPORT WORLD’S STARVING CHILDREN

Virtual Event with Musicians Tomorrow, November 19th, 9 AM to 5 PM EST

Malvern, Pennsylvania (USA), Nov. 18, 2020 (GLOBE NEWSWIRE) — Rajant Corporation, the provider of Kinetic Mesh® wireless networks, will host a fundraiser to bring awareness and donations for the United Nations Children’s Fund (UNICEF), a United Nations agency responsible for providing humanitarian and developmental aid to children in 192 countries worldwide. The virtual event is tomorrow, November 19th, 2020, and will be streamed “live” via Rajant’s YouTube channel from 9 AM to 5 PM EST.

The livestream features the full seven-hour performance of musical artists worldwide, and a GoFundMe page is available to accept donations. Rajant has pledged a donation of $25,000, and will additionally be matching the first $25,000 donated by their partners and customers. Artists include American Singer-Songwriter Morgan James,14-Piece Orchestra City Rhythm, and a host of other musical talent.

With countries in quarantine and closing borders due to COVID, the international food supply chain has been put at significant risk, and global poverty is expected to increase for the first time in decades, potentially reversing the worldwide fight against hunger and malnutrition. According to Rajant’s CEO and Co-founder Robert Schena, “Food is cheap in comparison to the price of starvation. Children are among the most prominent victims of hunger, and it impacts all aspects of their lives in profound ways. Children should not go to bed hungry because of a virus or any other reason, and this event is our way of shining a light on the issue. I was introduced to UNICEF, their story, and board member Jennifer Paradis Behle by Wendi Jay at UNICEF’s annual Snowflake Ball. This introduction led to our musical event. It is my hope and intention for Rajant employees, channel, and customers to unite in a way that is entertaining, informative, and fruitful in much needed monetary support of UNICEF.”

Jennifer Paradis Behle, who serves on the UNICEF USA’s New York Regional Board, will be among the day’s contributors sharing insights about UNICEF’s good works. Regarding Rajant’s musical fundraiser, “As an advocate for UNICEF, it brings me great joy to have Rajant’s support and sincere interest to make a difference. Mr. Schena and the Rajant team have embraced UNICEF’s tagline “For Every Child”. We are grateful to Rajant, online donors, and all the musicians devoting their time, talent, and financial assistance to the day’s success.”

####

 

About Rajant Corporation

Rajant Corporation is the exclusive provider of private wireless networks powered by the patented Kinetic Mesh® network, BreadCrumb® wireless nodes, and InstaMesh® networking software. With Rajant, customers can rapidly deploy a highly adaptable and scalable network that leverages the power of real-time data to deliver on-demand, mission-critical business intelligence. A low-latency, high-throughput and secure solution for a variety of data, voice, video, and autonomous applications, Rajant’s Kinetic Mesh networks provide industrial customers with full mobility, allowing them to take their private network applications and data anywhere. With successful deployments in more than 60 countries for customers in military, mining, ports, rail, oil & gas, petrochemical plants, municipalities, and agriculture. Rajant is headquartered in Malvern, Pennsylvania with additional facilities and offices in Kentucky and Arizona. For more information, visit Rajant.com or follow Rajant on LinkedIn and Twitter.

 

 

 

 

Attachment



Alice DiSanto
Rajant Corporation
914-582-8464
[email protected]

Medicure Announces Settlement of Patent Infringement Action

PR Newswire

WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. (“Nexus”) in the U.S. District Court for the Northern District of Illinois, which alleged infringement of Medicure’s U.S. Patent No. 6,770,660 (“the ‘660 patent”). As part of the settlement, Nexus has acknowledged that the ‘660 patent is valid, enforceable and infringed. The settlement results in the Company entering into a license agreement with Nexus with anticipated launch dates for Nexus’ generic products of November 1, 2022 for the 5 mg strength and January 1, 2023 for the 12.5 mg strength. The remaining terms of the settlement are confidential.

“We are pleased that we were able to settle this litigation in a cost-effective manner while protecting our AGGRASTAT brand and its intellectual property.” stated Dr. Albert Friesen, Chief Executive Officer of the Company and Chair of its Board of Directors.

The Company had filed the patent infringement action against Nexus alleging infringement of the ‘660 patent. The patent infringement action was in response to Nexus’ filing of an abbreviated new drug application (ANDA) seeking approval from the U.S. Food and Drug Administration (“FDA”) to market a generic version of AGGRASTAT® (tirofiban hydrochloride) injection before the expiration of the ‘660 patent. The ‘660 patent is listed in the FDA’s orange book with an expiry date of May 1, 2023.

AGGRASTAT® is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through the Company’s U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content:http://www.prnewswire.com/news-releases/medicure-announces-settlement-of-patent-infringement-action-301176527.html

SOURCE Medicure Inc.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Turquoise Hill Resources, Reta Pharmaceuticals, Evolus, and Las Vegas Sands and Encourages Investors to Contact the Firm

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Turquoise Hill Resources Ltd. (NYSE: TRQ), Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Evolus, Inc. (NASDAQ: EOLS), and Las Vegas Sands Corporation (NYSE: LVS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Turquoise Hill Resources Ltd. (NYSE: TRQ)

Class Period: July 17, 2018 to July 31, 2019

Lead Plaintiff Deadline: December 14, 2020

Turquoise Hill is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia (“Oyu Tolgoi”), which is the Company’s principal and only material resource property. Turquoise Hill’s subsidiary, Oyu Tolgoi LLC, holds a 66% interest in Oyu Tolgoi, and the remainder is held by the Government of Mongolia.

Rio Tinto plc and Rio Tinto Limited are operated and managed together as single economic unit and engage in mining and metals operations in approximately 35 countries. Through their subsidiaries, Rio Tinto owns 50.8% of Turquoise Hill. A Rio Tinto subsidiary, Rio Tinto International Holdings, Inc. (“Rio Tinto International” or “RTIH”; and collectively with Rio Tinto plc and Rio Tinto Limited, “Rio Tinto”), is also the manager of the Oyu Tolgoi project, including having responsibility for its development and construction.

On July 31, 2019, Turquoise Hill issued a press release and Management Discussion & Analysis (“MD&A”) making further disclosures about the status of the project, including that Turquoise Hill took a $600 million impairment charge and a substantial “deferred income tax recognition adjustment” tied to the Oyu Tolgoi project, and that it suffered a loss in the second quarter. The next day, before the market open, Rio Tinto issued a release concerning in part the project status, including that it had also taken an impairment charge related to the Oyu Tolgoi project, of $800 million.

Following this news, on August 1, 2019, Turquoise Hill’s common stock price closed at $0.53 per share, down 8.62% from the prior day’s closing price of $0.58 per share.

The complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements and omitted to disclose material facts regarding the Company’s business and operations. Specifically, defendants made false and or misleading statements and/or failed to disclose that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost and timing of production; (iii) the Company’s publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the Company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.

For more information on the Turquoise Hill class action go to: https://bespc.com/cases/TRQ

Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Class Period: October 15, 2019 to August 7, 2020

Lead Plaintiff Deadline: December 14, 2020

Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.

Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”).  Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the U.S. Food and Drug Administration (“FDA”).

On August 10, 2020, Reata issued a press release announcing its second quarter 2020 financial results, wherein it disclosed that the FDA is “not convinced that the MOXIe Part 2 results” of the Company’s study assessing omaveloxolone for the treatment of FA “will support a single study approval without additional evidence that lends persuasiveness to the results,” and that, “[i]n preliminary comments for [a] meeting, the FDA stated that [Defendants] will need to conduct a second pivotal trial that confirms the mFARS [modified Friedreich’s Ataxia Rating Scale] results of the MOXIe Part 2 study with a similar magnitude of effect.”

On this news, Reata’s stock price fell $51.79 per share, or 33.16%, to close at $104.41 per share on August 10, 2020.

The Complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that:  (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Reata class action go to: https://bespc.com/cases/REATA

Evolus
, Inc. (NASDAQ: EOLS)

Class Period: February 1, 2019 to July 6, 2020

Lead Plaintiff Deadline: December 15, 2020

Beginning in February 2019, Evolus embarked on a public campaign to hype the market right before the commercial launch of its sole leading product Jeuveau™. To secure an aggressive growth and an rapid influx of revenue, Evolus disseminated dozens of public statements in which they promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by Korean bioengineering company Daewoong through years of clinical research and millions of dollars’ worth of investment in research and development. Among other things, Evolus promised investors that it would attain the number two U.S. market position within 24 months of launch.

The investing public learned the real truth about Jeuveau™ on July 6, 2020 when the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, alleging that Evolus stole certain trade secrets to develop Jeuveau™. Coming as a great surprise to the unsuspecting investors, the ITC Judge found that Evolus misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. To make things even more catastrophic, the ITC Judge recommended a ten-year long ban on Evolus’ ability to import Jeuveau™ into the United States and a ten-year long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.

On this news Evolus’s share price declined sharply, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020. Following the news of the ITC’s Initial Final Determination and the subsequent price drop of Evolus’s common shares, several securities analysts downgraded Evolus’s rating and significantly lowered the Company’s price target.

The complaint, filed on October 16, 2020, alleges that throughout the Class period defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and failed to disclose to investors that: (i) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (ii) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (iii) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; which in turn (iv) seriously threatened Evolus’ ability to commercialize Jeuveau™ in the United States and generate revenue; and (v) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

For more information on the Evolus class action go to: https://bespc.com/cases/EOLS

Las Vegas Sands Corporation (NYSE: LVS)

Class Period: February 27, 2016 to September 15, 2020

Lead Plaintiff Deadline: December 21, 2020

Las Vegas Sands was founded in 1988 and is based in Las Vegas, Nevada. The Company, together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the U.S., which offer various amenities.

Las Vegas Sands’ properties include, among others, the Marina Bay Sands resort in Singapore, which operates a casino.

On July 19, 2020, Bloomberg News reported that Las Vegas Sands had settled a lawsuit brought by a former patron, Wang Xi (“Xi”), meeting his demand for a S$9.1 million ($6.5 million) payment. Xi reportedly sued the Marina Bay Sands casino in 2019 to recover S$9.1 million of his funds that the casino allegedly transferred to other patrons from his casino deposit accounts in 2015 without his approval, which triggered a probe into the casino by local authorities. Bloomberg News also reported that the U.S. Department of Justice (“DOJ”) “is also scrutinizing whether anti-money laundering procedures had been breached in the way the Singapore casino handles high rollers.”

On this news, Las Vegas Sands’ stock price fell $1.41 per share, or 2.9%, to close at $47.28 per share on July 20, 2020.

Then, on September 16, 2020, Bloomberg reported that Marina Bay Sands “has hired a law firm to conduct a new investigation into employee transfers of more than $1 billion in gamblers’ money to third parties[.]” The article quoted the Singapore Casino Regulatory Authority (“CRA”) as stating that “there were weaknesses in [Marina Bay Sands’] casino control measures pertaining to fund transfers[.]”

On this news, Las Vegas Sands’ stock price fell $2.18 per share, or 4.2%, to close at $49.67 per share on September 16, 2020.

The complaint, filed on October 22, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands’ casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands’ casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company’s anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Las Vegas Sands class action go to: https://bespc.com/cases/LVS

About
Bragar
Eagel
& Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com



Elys Game Technology Provides Call Coordinates for Annual Meeting of Shareholders

Elys Game Technology Provides Call Coordinates for Annual Meeting of Shareholders

NEW YORK–(BUSINESS WIRE)–
Elys Game Technology, Corp. (formerly Newgioco Group, Inc.) (“Elys” or the “Company”) (Nasdaq:ELYS), an interactive gaming and sports betting technology company, provides update for its annual meeting of shareholders to be held on Friday, November 20, 2020 at 10 a.m. (Eastern Standard Time) (the “Meeting”) at the Company’s offices, 130 Adelaide Street West, Suite 701, Toronto, Ontario Canada. The COVID-19 situation is dynamic and continues to evolve daily and we intend to take precautions for social distancing for those that attend the Meeting. The Company urges all Shareholders to vote by proxy in advance of the Meeting at www.proxyvote.com by entering the code provided with the proxy materials and for those who cannot attend the Meeting they can listen to the Meeting through the live conference call coordinates as follows:

Canada and US:

1-833-353-8610

Italy, Austria, U.K. and Switzerland:

00 800 0066 8888 Includes San Marino & Vatican City

 

 

Participant: 3739385 #

 

Participants should dial in approximately 5 to 10 minutes prior to the scheduled start time.

Registered Shareholders or duly appointed proxyholders who will attend the Meeting will be permitted to vote at the Meeting. Those listening by telephone will not be able to vote.

About Elys Game Technology, Corp.

Elys Game Technology, Corp., is a B2B global gaming technology company operating in multiple countries worldwide, with B2C online and land-based gaming operations in Italy. In Italy, Elys offers its clients a full suite of leisure gaming products and services, such as sports betting, esports, virtual sports, online casino, poker, bingo, interactive games and slots.

The Company’s innovative wagering solution services online operators, casinos, retail betting establishments and franchise distribution networks. The Company has completed the product regulatory requirements to commence B2B operations in the United States. Additional information is available on our corporate website at www.elysgame.com.

Investors may also find us on Twitter @ELYS_gaming.

Elys Game Technology, Corp.

Michele Ciavarella, Chief Executive Officer

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Other Consumer Retail Audio/Video Software Networks Internet Online Retail Hardware Consumer Electronic Design Automation Data Management Consumer Electronics Technology Entertainment Mobile/Wireless General Sports Restaurant/Bar Sports General Entertainment

MEDIA:

Logo
Logo

Bilibili Inc. Announces Third Quarter 2020 Financial Results

SHANGHAI, China, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI), a leading online entertainment platform for young generations in China, today announced its unaudited financial results for the third quarter ended September 30, 2020.

Third Quarter 2020
Highlights:

  • Total net revenues reached RMB3,225.7 million (US$475.1 million), a 74% increase from the same period in 2019.
  • Average monthly active users (MAUs) reached 197.2 million, and mobile MAUs reached 183.5 million, representing increases of 54% and 61%, respectively, from the same period in 2019.
  • Average daily active users (DAUs) reached 53.3 million, a 42% increase from the same period in 2019.
  • Average monthly paying users (MPUs1
    ) reached 15.0 million, an 89% increase from the same period in 2019.

“We are excited to announce another great quarter with exceptional growth in both user numbers and our top line,” said Mr. Rui Chen, Chairman of the Board and Chief Executive Officer of Bilibili. “Our effective user growth strategy and expanding content library helped us to reach an even broader audience. In August, our MAUs exceeded 200 million, marking a new monthly record. This milestone is just the beginning. We envision that the inevitable video-lization trend will lead to great opportunities for Bilibili to grow and expand as the go-to platform for online content in China. As we leverage our core capabilities in providing engaging content and community experience, we are committed to further improving our brand equity and capturing this market opportunity. We believe the investments we are making now to increase our stronghold in China’s entertainment market will yield considerable and sustainable return in the long run.”

Mr. Sam Fan, Chief Financial Officer of Bilibili, said, “Our strong user growth continues fueling our top line expansion. In the third quarter, we achieved another quarter of record high revenue, which reached RMB3.2 billion, up 74% year-over-year, once again beating the top end of our guidance. As we rolled out more premium content and services, more traffic was converted to paying users and our overall paying ratio improved. MPUs were 15.0 million in the third quarter, demonstrating an 89% increase year-over-year. We are also glad to have achieved gross margin improvement for the sixth-consecutive quarter, reaching 23.6%. Looking ahead, we are committed to executing our growth strategy and investing in our future growth, which we believe will bring long-term value to all of our stakeholders.”

Third Quarter 2020
Financial Results


Total net revenues. Total net revenues were RMB3,225.7 million (US$475.1 million), representing an increase of 74% from the same period of 2019.

Mobile games.
Revenues from mobile games were RMB1,275.1 million (US$187.8 million), representing an increase of 37% from the same period of 2019. The increase was primarily due to the successful newly launched mobile games.

Value-added services (VAS) (formerly known as Live broadcasting and VAS). Revenues from VAS were RMB979.6 million (US$144.3 million), representing an increase of 116% from the same period of 2019, mainly attributable to the Company’s enhanced monetization efforts, led by increases in the number of paying users for the Company’s premium membership program, live broadcasting services and other value-added services.

Advertising.
Revenues from advertising were RMB557.5 million (US$82.1 million), representing an increase of 126% from the same period of 2019. This increase was primarily attributable to the increasing number of advertisers, which was driven by further recognition of Bilibili’s brand name in China’s online advertising market.

E-commerce and others.
Revenues from e-commerce and others were RMB413.4 million (US$60.9 million), representing an increase of 83% from the same period of 2019, primarily attributable to the increase in sales of products through the Company’s e-commerce platform.

Cost of revenues.
Cost of revenues was RMB2,464.1 million (US$362.9 million), representing an increase of 63% compared to the same period of 2019. Revenue-sharing cost, a key component of cost of revenues, was RMB1,179.5 million (US$173.7 million), representing an increase of 77% from the same period in 2019.

Gross profit.
Gross profit was RMB761.6 million (US$112.2 million), representing an increase of 117% from the same period in 2019, which was primarily due to increased net revenues.

Total operating expenses.
Total operating expenses were RMB1,844.9 million (US$271.7 million), representing an increase of 138% from the same period of 2019.

Sales and marketing expenses. Sales and marketing expenses were RMB1,190.4 million (US$175.3 million), representing a 227% increase year-over-year. The increase was primarily attributable to increased channel and marketing expenses associated with Bilibili’s app and brand, as well as promotional expenses for the Company’s mobile games. The increase was also attributable to the increase in headcount in sales and marketing personnel.

General and administrative expenses. General and administrative expenses were RMB253.5 million (US$37.3 million), representing a 55% increase year-over-year. The increase was primarily due to the increased headcount in general and administrative personnel, increased share-based compensation expenses, increased allowance for doubtful accounts, higher rental expenses and other general and administrative expenses.

Research and development expenses. Research and development expenses were RMB401.0 million (US$59.1 million), representing a 62% increase year-over-year. The increase was primarily due to increased headcount in research and development personnel and increased share-based compensation expenses.

Loss from operations.
Loss from operations was RMB1,083.3 million (US$159.6 million), compared to RMB423.1 million in the same period of 2019.

Income tax expense.
Income tax expense was RMB17.3 million (US$2.5 million), compared to RMB8.1 million in the same period of 2019.

Net loss.
Net loss was RMB1,100.9 million (US$162.1 million), compared to RMB405.7 million in the same period of 2019.

Adjusted net loss2.
Adjusted net loss, which is a non-GAAP measure that excludes share-based compensation expenses, amortization expense related to intangible assets acquired through business acquisitions and income tax related to intangible assets acquired through business acquisitions, was RMB990.0 million (US$145.8 million), compared to RMB343.1 million in the same period of 2019.

Basic and diluted EPS and adjusted
basic and diluted EPS2. Basic and diluted net loss per share were RMB3.08 (US$0.45), compared to RMB1.24 in the same period of 2019. Adjusted basic and diluted net loss per share were RMB2.76 (US$0.41), compared to RMB1.05 in the same period of 2019.

Cash and cash equivalents, time deposits and short-term investments.
As of September 30, 2020, the Company had cash and cash equivalents, time deposits, as well as short-term investments of RMB14.1 billion (US$2.1 billion), compared to RMB8.1 billion as of December 31, 2019.

Recent Development

In August 2020, the Company entered into a Subscription Agreement with Huanxi Media Group Limited (“Huanxi Media”) (HKEX: 1003) for 346,626,954 newly issued ordinary shares of Huanxi Media for an aggregate consideration of approximately HK$513.0 million (US$66.2 million). Upon the completion of this transaction, the Company will beneficially own approximately 9.90% of Huanxi Media’s total issued shares.

Simultaneous with the execution of the Subscription Agreement, two wholly-owned subsidiaries of the Company entered into a five-year business cooperation agreement with a wholly-owned operating subsidiary of Huanxi Media, pursuant to which Bilibili and Huanxi Media will pursue collaboration opportunities in online entertainment for the Chinese market, including films and TV drama series, and developing derivative intellectual property rights of the films and other TV programs owned by Huanxi Media.

Outlook

For the fourth quarter of 2020, the Company currently expects net revenues to be between RMB3.60 billion and RMB3.70 billion.

The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates, which are all subject to various uncertainties, including those related to the ongoing COVID-19 pandemic.

1 The paying users are calculated by number of users who paid for games, live broadcasting, premium membership, Bilibili Comic and Maoer, after eliminating duplicates of users paid for multiple services other than users of Maoer. The Company adds the number of paying users of Maoer toward its total paying users without eliminating duplicates.

2 Adjusted net loss and adjusted basic and diluted EPS are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section of “Use of Non-GAAP Financial Measures” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Conference Call

The Company’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on November 18, 2020 (9:00 AM Beijing/Hong Kong time on November 19, 2020).

Details for the conference call are as follows:

Event Title: Bilibili Inc. Third Quarter 2020 Earnings Conference Call
Conference ID:  4395658
Registration Link:
http://apac.directeventreg.com/registration/event/4395658

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, an event passcode, and a unique registrant ID, which will be used to join the conference call.

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.bilibili.com.

A replay of the conference call will be accessible by phone two hours after the conclusion of the live call at the following numbers, until November 25, 2020:

United States: +1-855-452-5696
International: +61-2-8199-0299
Hong Kong: 800-963-117
China: 400-632-2162
Replay Access Code: 4395658

About Bilibili Inc.


Bilibili represents an iconic brand of online entertainment with a mission to enrich the everyday life of young generations in China. Bilibili is a full-spectrum online entertainment world covering a wide array of genres and media formats, including videos, live broadcasting and mobile games. Bilibili provides an immersive entertainment experience and high-quality content that caters to the evolving and diversified interests of its users and communities, and has built its platform based on the strong emotional connections of Bilibili’s users to its content and communities.

For more information, please visit: http://ir.bilibili.com.

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as adjusted net loss, adjusted net loss per share and per ADS, basic and diluted, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business by excluding the impact of share-based compensation expenses, amortization expense related to intangible assets acquired through business acquisitions and income tax related to intangible assets acquired through business acquisitions, which are non-cash charges. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.

The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB6.7896 to US$1.00, the exchange rate on September 30, 2020 set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue,” or other similar expressions. Among other things, Outlook and quotations from management in this announcement, as well as Bilibili’s strategic and operational plans, contain forward-looking statements. Bilibili may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Bilibili’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the impact of the COVID-19 pandemic on the Bilibili’s business, results of operations, financial condition, and stock price; Bilibili’s strategies; Bilibili’s future business development, financial condition and results of operations; Bilibili’s ability to retain and increase the number of users, members and advertising customers, provide quality content, products and services, and expand its product and service offerings; competition in the online entertainment industry; Bilibili’s ability to maintain its culture and brand image within its addressable user communities; Bilibili’s ability to manage its costs and expenses; PRC governmental policies and regulations relating to the online entertainment industry, general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:


In China:


Bilibili Inc.
Juliet Yang
Tel: +86-21-2509 9255 Ext. 8523
E-mail: [email protected]

The Piacente Group, Inc.
Emilie Wu
Tel: +86-21-6039-8363
E-mail: [email protected]


In the United States:

The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]

 
BILIBILI INC.

Unaudited Condensed Consolidated Statements of Operations

(All amounts in thousands, except for share and per share data)

 
  For the Three Months Ended   For the Nine Months Ended
  September 30, June 30, September 30,   September 30, September 30,
  2019  2020  2020    2019  2020 
  RMB RMB RMB   RMB RMB
             
Net revenues:            
Mobile games 933,133   1,247,977   1,275,136     2,726,444   3,673,726  
Value-added services
(formerly known as Live broadcasting and VAS)
452,518   825,251   979,633     1,070,183   2,598,437  
Advertising 247,186   348,572   557,510     527,421   1,120,348  
E-commerce and others 226,126   195,801   413,434     446,105   766,338  
Total net revenues 1,858,963   2,617,601   3,225,713     4,770,153   8,158,849  
Cost of revenues (1,507,684 ) (2,013,588 ) (2,464,138 )   (3,977,819 ) (6,262,797 )
Gross profit 351,279   604,013   761,575     792,334   1,896,052  
             
Operating expenses:            
Sales and marketing expenses (363,859 ) (675,092 ) (1,190,354 )   (785,350 ) (2,471,403 )
General and administrative expenses (163,217 ) (208,411 ) (253,475 )   (432,973 ) (633,263 )
Research and development expenses (247,308 ) (330,628 ) (401,030 )   (649,243 ) (1,028,993 )
Total operating expenses (774,384 ) (1,214,131 ) (1,844,859 )   (1,867,566 ) (4,133,659 )
Loss from operations (423,105 ) (610,118 ) (1,083,284 )   (1,075,232 ) (2,237,607 )
             
Other income/(expenses):            
Investment income, net 513   31,423   14,245     97,028   19,187  
Interest income 52,018   23,504   18,150     126,396   68,306  
Interest expense (16,047 ) (22,671 ) (35,961 )   (31,685 ) (73,804 )
Exchange (losses)/gains (5,640 ) 4,213   11,406     (8,588 ) 28,329  
Others, net (5,362 ) 14,734   (8,176 )   4,663   23,891  
Total other income/(expenses), net 25,482   51,203   (336 )   187,814   65,909  
Loss before income tax (397,623 ) (558,915 ) (1,083,620 )   (887,418 ) (2,171,698 )
Income tax (8,082 ) (11,939 ) (17,277 )   (28,941 ) (38,608 )
Net loss (405,705 ) (570,854 ) (1,100,897 )   (916,359 ) (2,210,306 )
Accretion to redeemable noncontrolling interests   (1,760 ) (1,262 )     (4,292 )
Net (gain)/loss attributable to noncontrolling interests (1,652 ) 5,966   20,143     10,227   30,693  
Net loss attributable to the Bilibili Inc.’s shareholders (407,357 ) (566,648 ) (1,082,016 )   (906,132 ) (2,183,905 )
             
             
             
Net loss per share, basic (1.24 ) (1.63 ) (3.08 )   (2.82 ) (6.36 )
Net loss per ADS, basic (1.24 ) (1.63 ) (3.08 )   (2.82 ) (6.36 )
Net loss per share, diluted (1.24 ) (1.63 ) (3.08 )   (2.82 ) (6.36 )
Net loss per ADS, diluted (1.24 ) (1.63 ) (3.08 )   (2.82 ) (6.36 )
Weighted average number of ordinary shares, basic 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ADS, basic 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ordinary shares, diluted 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ADS, diluted 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
             

The accompanying notes are an integral part of this press release.

             
BILIBILI INC.


NOTES TO UNAUDITED FINANCIAL INFORMATION

(All amounts in thousands, except for share and per share data)

             
  For the Three Months Ended   For the Nine Months Ended
  September 30, June 30, September 30,   September 30, September 30,
  2019 2020 2020   2019 2020
  RMB RMB RMB   RMB RMB
             
             
Share-based compensation expenses included in:            
Cost of revenues 6,381 7,256 10,296   17,566 24,427
Sales and marketing expenses 3,424 11,212 10,757   10,324 28,728
General and administrative expenses 21,855 41,421 41,509   52,210 109,346
Research and development expenses 19,688 26,758 33,804   50,896 76,036
Total 51,348 86,647 96,366   130,996 238,537
             

 
BILIBILI INC.

Unaudited Condensed Consolidated Balance Sheets

(All amounts in thousands, except for share and per share data)

     
  December 31, September 30,
  2019 2020
  RMB RMB
     
Assets    
Current assets:    
Cash and cash equivalents 4,962,660 5,927,471
Time deposits 1,844,558 4,910,762
Accounts receivable, net 744,845 1,186,171
Prepayments and other current assets 1,511,191 1,810,870
Short‑term investments 1,260,810 3,260,895
Total current assets 10,324,064 17,096,169
Non‑current assets:    
Property and equipment, net 516,087 787,701
Production cost, net 443,533 666,281
Intangible assets, net 1,657,333 2,368,253
Goodwill 1,012,026 1,295,786
Long‑term investments, net 1,251,129 1,548,769
Other long-term assets 312,395 583,488
Total non‑current assets 5,192,503 7,250,278
Total assets 15,516,567 24,346,447
Liabilities    
Current liabilities:    
Accounts payable 1,904,042 2,932,801
Salary and welfare payables 355,936 530,305
Taxes payable 67,856 111,132
Short-term loan 100,000
Deferred revenue 1,369,000 2,117,864
Accrued liabilities and other payables 575,763 1,217,655
Total current liabilities 4,272,597 7,009,757
Non-current liabilities:    
Long-term debt 3,414,628 8,699,504
Other long-term liabilities 192,882 226,949
Total non-current liabilities 3,607,510 8,926,453
Total liabilities 7,880,107 15,936,210
     
Total Bilibili Inc.’s shareholders’ equity  7,052,484  8,212,321
Noncontrolling interests 583,976  197,916
Total shareholders’
equity
7,636,460  8,410,237
     
Total liabilities and shareholders’ equity 15,516,567 24,346,447
     

 
BILIBILI INC.

Unaudited Reconciliations of GAAP and Non-GAAP Results

(All amounts in thousands, except for share and per share data)

 
  For the Three Months Ended   For the Nine Months Ended
  September 30, June 30, September 30,   September 30, September 30,
  2019  2020  2020    2019  2020 
  RMB RMB RMB   RMB RMB
             
Net loss (405,705 ) (570,854 ) (1,100,897 )   (916,359 ) (2,210,306 )
Add:            
Share-based compensation expenses 51,348   86,647   96,366     130,996   238,537  
Amortization expense related to intangible assets
  acquired through business acquisitions
11,305   8,472   16,007     40,795   32,951  
Income tax related to intangible assets acquired
  through business acquisitions
    (1,514 )     (1,514 )
Adjusted net loss (343,052 ) (475,735 ) (990,038 )   (744,568 ) (1,940,332 )
             
Net loss attributable to the Bilibili Inc.’s shareholders (407,357 ) (566,648 ) (1,082,016 )   (906,132 ) (2,183,905 )
Add:            
Share-based compensation expenses 51,348   86,647   96,366     130,996   238,537  
Amortization expense related to intangible assets
  acquired through business acquisitions
11,305   8,472   16,007     40,795   32,951  
Income tax related to intangible assets acquired
  through business acquisitions
    (1,514 )     (1,514 )
Adjusted net loss attributable to the Bilibili Inc.’s shareholders (344,704 ) (471,529 ) (971,157 )   (734,341 ) (1,913,931 )
Adjusted net loss per share, basic (1.05 ) (1.35 ) (2.76 )   (2.28 ) (5.58 )
Adjusted net loss per ADS, basic (1.05 ) (1.35 ) (2.76 )   (2.28 ) (5.58 )
Adjusted net loss per share, diluted (1.05 ) (1.35 ) (2.76 )   (2.28 ) (5.58 )
Adjusted net loss per ADS, diluted (1.05 ) (1.35 ) (2.76 )   (2.28 ) (5.58 )
Weighted average number of ordinary shares, basic 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ADS, basic 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ordinary shares, diluted 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  
Weighted average number of ADS, diluted 327,231,439   348,634,400   351,301,703     321,634,678   343,156,614  



Suncor Energy declares dividend

All financial figures are in Canadian dollars.

CALGARY, Alberta, Nov. 18, 2020 (GLOBE NEWSWIRE) — Suncor Energy’s Board of Directors has approved a quarterly dividend of $0.21 per share on its common shares, payable December 24, 2020 to shareholders of record at the close of business on December 3, 2020.

Suncor Energy is Canada’s leading integrated energy company. Suncor’s operations include oil sands development and upgrading, offshore oil and gas production, petroleum refining, and product marketing under the Petro-Canada brand. A member of Dow Jones Sustainability indexes, FTSE4Good and CDP, Suncor is working to responsibly develop petroleum resources while also growing a renewable energy portfolio. Suncor is listed on the UN Global Compact 100 stock index. Suncor’s common shares (symbol: SU) are listed on the Toronto and New York stock exchanges.

For more information about Suncor, visit our web site at suncor.com, follow us on Twitter @Suncor

Media inquiries:
1-833-296-4570
[email protected]

Investor inquiries:
800-558-9071
[email protected]



PyroGenesis Receives Final Approval to Graduate to the Toronto Stock Exchange

MONTREAL, Nov. 18, 2020 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://www.pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that it has received final approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (“TSXV”) and list its common shares (“Common Shares”) on the TSX.

The Company’s Common Shares will be listed for trading on the TSX at the opening of markets on Friday, November 20, 2020 under its current trading symbol “PYR”. In connection with the listing of the Common Shares on the TSX, the last day of trading on the TSXV will be Thursday, November 19, 2020 and the Common Shares will be delisted from the TSXV effective as of the commencement of trading on the TSX. Shareholders will not be required to take any action in connection with the graduation and listing on the TSX.

“It is indeed a pleasure to be able to announce today that PyroGenesis is uplisting to the most senior exchange in Canada, the TSX, this Friday. We are very pleased to announce this significant achievement for PyroGenesis that confirms our development and growth as a company. I want to take this opportunity to thank the team at PyroGenesis, as well as the professionals who guided us; particularly our legal advisors,” said Mr. Peter Pascali, CEO and Chair of PyroGenesis. “We also would like to thank the TSXV for providing us with the platform to grow into the Company we are today, and attract a solid stable of investors. It is important to recognize that a platform, be it the TSXV or the TSX, is only part of the equation. The PyroGenesis team, technologies, as well as the solid base of business, and business relationships we have developed, while on the TSXV, are well suited for this graduation.”

“We look forward to this uplisting and the additional credibility that the Company will gain by trading on the most significant stock exchange in Canada, which is also one of the largest in North America1,” added Ms. Rodayna Kafal, VP IR & Comms. and Director of PyroGenesis. “We anticipate that this step change will provide PyroGenesis with greater visibility in the marketplace and access to a broader and more diverse range of international and institutional investors.”

About PyroGenesis Canada Inc

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to
a number of
risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks
detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at

www.sedar.com,

or at


www.otcmarkets.com



.

Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws
.
Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release
.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President, IR/Comms. and Strategic BD
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

____________________

1 https://www.investopedia.com/terms/t/toronto-stock-exchange-tsx.asp#:~:text=Established%20in%201852%20and%20owned,significant%20stock%20exchange%20in%20Canada



Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully completed a A$29.6 million a private placement of ordinary shares to professional and institutional investors (Placement).

Use of Funds

The Company will use the proceeds from the Placement to finance its LAG-3 related clinical programs in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321), including the expansion of the Phase II TACTI-002 study through an additional 74 patients with 1st line NSCLC and a new Phase II clinical trial in 1st line HNSCC.  Details of these expansion plans were also announced today.

The funds will also be used for the cell-line development of IMP761, R&D, manufacturing, the offering costs and working capital purposes.

Placement

123.2 million new fully paid ordinary shares (“New Shares“) will be issued under the Placement at an issue price of A$0.24 per New Share (representing a 11.2% discount to the volume weighted average price (“VWAP“) of the Company’s ordinary shares as traded on ASX over the 30 days up to and including Tuesday, November 17, 2020), raising a total of A$29.6 million before transaction-related expenses.

Timetable

Settlement of the Placement is expected to occur on Tuesday, 24 November 2020 with the issue of New Shares expected to occur on Wednesday 25 November 2020. The New Shares issued under the Placement will rank pari passu with the Company’s existing fully paid ordinary shares on issue as at their date of issue.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States or to US Persons (as defined in Rule 902(k) under the US Securities Act) except in transactions (i) registered under the US Securities Act or (ii) exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.

This announcement contains certain “forward-looking statements” including statements regarding the Company’s intent, belief or current expectations with respect to Immutep’s business and operations, market conditions, results of operations, financial condition, and risk management practices. The words “likely”, “expect”, “aim”, “should”, “could”, “may”, “anticipate”, “predict”, “believe”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this announcement include statements regarding the outcome and effects of the Placement and statements regarding Immutep’s future financial performance and results. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in the Company. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this announcement.



Reinvent Technology Partners Z Announces Pricing of $200 Million Initial Public Offering

Reinvent Technology Partners Z Announces Pricing of $200 Million Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Reinvent Technology Partners Z (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “RTPZ.U” beginning November 19, 2020. Each unit consists of one Class A ordinary share and one-fifth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the NYSE under the symbols “RTPZ” and “RTPZ WS,” respectively.

The Company, led by Reid Hoffman, Mark Pincus, and Michael Thompson, is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search for a target business operating in the technology sectors.

Morgan Stanley is acting as lead bookrunning manager for the offering. C.L. King & Associates is acting as co-manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Morgan Stanley, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, Email: [email protected].

A registration statement relating to the securities became effective on November 18, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is expected to close on November 23, 2020, subject to customary closing conditions.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s preliminary prospectus for the Company’s offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Finance Internet Professional Services Technology Software

MEDIA:

Logo
Logo

Northrop Grumman Board Declares Quarterly Dividend

FALLS CHURCH, Va., Nov. 18, 2020 (GLOBE NEWSWIRE) — The board of directors of Northrop Grumman Corporation (NYSE: NOC) declared a quarterly dividend of $1.45 per share on Northrop Grumman common stock, payable Dec. 16, 2020, to shareholders of record as of the close of business Nov. 30, 2020.

Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 90,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services.

Contact: Tim Paynter (Media)
  703-280-2720 (office)
  [email protected]
   
  Todd Ernst (Investors)
  703-280-4535 (office)
  [email protected]